Anzeige
Mehr »
Freitag, 14.08.2026 - Börsentäglich über 12.000 News
Die Bohrungen sind fast abgeschlossen. Was jetzt kommt, könnte noch wichtiger sein
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1CZA8 | ISIN: IL0011063760 | Ticker-Symbol:
NASDAQ
14.08.26 | 15:30
0,926 US-Dollar
-4,52 % -0,044
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
INTERCURE LTD Chart 1 Jahr
5-Tage-Chart
INTERCURE LTD 5-Tage-Chart

Aktuelle News zur INTERCURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiIntercure Ltd. - 6-K, Report of foreign issuer3
04.08.Intercure Ltd. - 6-K, Report of foreign issuer-
22.07.Intercure Ltd. - 6-K, Report of foreign issuer1
22.06.InterCure secures up to NIS 54M financing1
22.06.InterCure secures $7.4M funding commitment, may rise to $18.6M4
INTERCURE Aktie jetzt für 0€ handeln
22.06.Intercure Ltd. - 6-K, Report of foreign issuer-
22.06.InterCure Ltd: InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds1
15.06.InterCure schließt erste Tranche der Botanico-Übernahme ab1
15.06.Intercure Ltd. - 6-K, Report of foreign issuer1
15.06.InterCure Ltd: InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition244First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing...
► Artikel lesen
01.05.InterCure reports FY results1
01.05.InterCure Ltd: InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow245The Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NIS 17 million in positive operating cash flow, reflecting strong resilience...
► Artikel lesen
30.04.Intercure Ltd. - 20-F, Annual and transition report of foreign private issuers-
03.03.InterCure receives Nasdaq notice for minimum bid price deficiency1
03.03.Intercure Ltd. - 6-K, Report of foreign issuer1
03.03.InterCure receives Nasdaq notification regarding minimum bid requirement1
03.03.InterCure Ltd: InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement398NEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced that on February 25, 2026 the Company received...
► Artikel lesen
19.02.Intercure Ltd. - 6-K, Report of foreign issuer3
19.02.InterCure Ltd: InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million905InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA2, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents...
► Artikel lesen
19.02.InterCure Ltd.: InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million1
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1